Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
13.95
+0.21 (1.53%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $341.85 million as of August 14, 2026. Its market cap has increased by 64.30% in one year.
Market Cap
341.85M
Enterprise Value
160.45M
1-Year Change
64.30%
Ranking
Category
Stock Price
$13.95
ChartMarket Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $341.85M, a decrease of -91.72%. That is a compound annual growth rate of -38.28%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 14, 2026 | 341.85M | -47.72% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| DiaMedica Therapeutics | 364.00M |
| Abeona Therapeutics | 362.83M |
| Sutro Biopharma | 353.34M |
| Century Therapeutics | 349.48M |
| Vicore Pharma Holding AB | 343.68M |
| Clinuvel Pharmaceuticals | 341.43M |
| SAB Biotherapeutics | 341.20M |
| Immuneering | 336.43M |